|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To characterize the mechanisms of interaction between proteasome inhibitors and TRAIL protein, we evaluated the effects of combined treatment with the proteasome inhibitors bortezomib and MG132 and TRAIL protein on two TRAIL-resistant human colon cancer cell lines, DLD1-TRAIL/R and LOVO-TRAIL/R.
|
16082182 |
2005 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that TRAIL-targeted therapies may be used to enhance conventional chemotherapy regimens in colon cancer regardless of tumor p53 status.
|
16373718 |
2005 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, Verticillin A effectively sensitized metastatic human colon carcinoma xenograft to TRAIL-mediated growth inhibition in vivo.
|
21911457 |
2011 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we showed the differential TRAIL responsiveness of human prostate adenocarcinoma PC3 and human colon carcinoma KM12 cells and their respective highly metastatic PC3-MM2 and KM12L4A sublines and investigated the mechanism underlying high susceptibility of human metastatic cancer cells to TRAIL.
|
21513580 |
2011 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, we established a TRAIL-resistant human colon cancer DLD-1 cell line to clarify the mechanisms of TRAIL-resistance and developed agents to cancel its machinery.
|
26304927 |
2015 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells.
|
20661477 |
2010 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.
|
23732517 |
2013 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sensitization of human colon cancer cells to TRAIL-mediated apoptosis.
|
11309649 |
2001 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The in vivo capability of 2-14 to sensitize colon cancer cells to TRAIL-induced apoptosis was evaluated in a syngenic colon cancer model in which CT26-derived grafts were induced in mice.
|
21817114 |
2011 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we found that TRAIL could induce PARP-1 cleavage and apoptosis in colon cancer HCT116 cell, but HT-29 cell was not sensitive to TRAIL.
|
31558316 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lactobacillus casei Exerts Anti-Proliferative Effects Accompanied by Apoptotic Cell Death and Up-Regulation of TRAIL in Colon Carcinoma Cells.
|
26849051 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.
|
12865931 |
2003 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate resistance that develops in cancer cells during treatment with adenoviral vectors expressing proapoptotic genes, we repeatedly treated the human colon cancer cell line DLD1 with adenoviral vectors expressing the human Bax gene and the human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
|
12215894 |
2002 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the combination of 3-BP and TRAIL can be a promising therapeutic strategy for treatment of colon cancer.
|
31491344 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that gefitinib and TRAIL in combination produce a potent synergistic effect on TRAIL-sensitive human colon cancer HCT116 cells and an additive effect on TRAIL-resistant HT-29 cells.
|
27629794 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver.
|
16478647 |
2007 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we have tested LUV-TRAIL in several human colon cancer cell lines with different sensitivity to sTRAIL.
|
27725224 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we analyzed side by side apoptotic and non-apoptotic signaling induced by TRAIL or the agonistic TRAIL-R-specific antibodies Mapatumumab (anti-TRAIL-R1) and Lexatumumab (anti-TRAIL-R2) in the two isogenic colon carcinoma cell lines HCT116 p53+/+ and p53-/-.
|
30947287 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Niacin alleviates TRAIL-mediated colon cancer cell death via autophagy flux activation.
|
26517672 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Agonists of an ecdysone-inducible mammalian expression system inhibit Fas Ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO.
|
16082389 |
2006 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clitocine potentiates TRAIL-mediated apoptosis in human colon cancer cells by promoting Mcl-1 degradation.
|
27421828 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Colon cancer (HCT116, SW480), prostate cancer (PC3, LNCaP) and leukemia (K562) cells were treated with STI571 and TRAIL.
|
22462553 |
2012 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway.
|
25113506 |
2014 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we engineered murine MSCs (mMSCs) to express a secreted form of the TNF-related apoptosis-inducing ligand (TRAIL), which is a potent inducer of apoptosis in tumor cells, and tested these MSCs, termed MSC.sTRAIL, in combination with conventional chemotherapeutic drug treatment in colon cancer models.
|
23429289 |
2013 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRAIL is pro-apoptotic on colon cancer cells, while not cytotoxic towards normal healthy cells.
|
26771233 |
2016 |